English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Received: October 23, 2017; Accepted: November 06, 2017; Published: November 10, 2017 According to the National Institute for Health and Care Excellence (NICE), GPs should use a 10-year cardiovascular disease (CVD) risk estimate, the QRISK®2 score, to determine whether patients should be started on statins. Sam Finnikin and colleagues [1] from the University of Birmingham examined the records of over 1.4 million patients aged over 40 years, and found that just over 10% had a recorded CVD risk score and that 15% had been started on statins since 2012. However, only about a quarter of these newly-treated patients had a record of a risk assessment in their notes, and of those whose risk scores had been calculated, only a minority had started treatment. Even among high-risk patients, only 35% had been initiated on a statin. This study shows that there is still potential under treatment of patients at high risk of CVD.

Cardiovascular disease primary prevention failure: A sixth of patients with a QRISK2 score below 10% were started on statins, despite the guidelines